Posted by Michael Wonder on 20 Feb 2020
ICER to assess treatments for bladder cancer
20 February 2020 - Report will be subject of a Midwest CEPAC meeting in September 2020; open Input now being accepted until 10 March 2020.
The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of nadofaragene firadenovec (Instiladrin, FKD Therapies Oy and Ferring Pharmaceuticals) for the treatment of bladder cancer.
Nadofaragene firadenovec has received a fast track and breakthrough therapy designation from the FDA, with an anticipated decision expected in mid-2020.
